{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075707","form_type":"8-K/A","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.177291+00:00","generated_at":"2026-05-17T16:46:20.314807+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M","bullets":["Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.","Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.","R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.","VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.","Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075707","json":"https://secwatch.observer/filing/0001104659-25-075707.json","markdown":"https://secwatch.observer/filing/0001104659-25-075707.md","text":"https://secwatch.observer/filing/0001104659-25-075707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/0001104659-25-075707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/tm2523009d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:46:20.314807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}